Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System.

An X., Zhou Q., Sheng S., Deng A., Liu H., Wang X.

Animal Study on Osteoarthritis, Cartilage Damage, Meniscus Injury, Chronic Inflammation, published in Aging Dis (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aging Dis (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39908269
DOI
10.14336/AD.2024.10016

Abstract (original English)

Osteoarthritis (OA) is a prevalent degenerative joint disease that significantly impacts the quality of life in the elderly. Traditional Chinese medicine, particularly Medicinal Cyathula Root and its active component Cyaonoside A (CyA), has been utilized to treat OA by promoting chondrocyte proliferation, inhibiting inflammatory factors, and maintaining joint homeostasis. Concurrently, mesenchymal stem cells (MSC) derived from placental umbilical cord, bone marrow, and adipose tissue have gained attention for their potential in OA treatment due to their chondrogenic differentiation capabilities. This study explored the therapeutic synergy of CyA and MSC for enhanced cartilage regeneration. Optimal chondrogenic differentiation was achieved by treating MSC with 0.5 mg/mL CyA for 3 days, significantly increasing the expression of key cartilage-specific genes ACAN, COL2A, and SOX9. Comparative gene expression and pathway analyses revealed that CyA-induced MSC (C-MSC) modulate critical signaling pathways, including TGF-β, PI3K-Akt, and Wnt, demonstrating their potential in cartilage repair. Furthermore, C-MSC-derived exosomes exhibited superior anti-inflammatory and anti-apoptotic effects compared to MSC-derived exosomes in IL-1β-treated human chondrocytes, enhancing chondrogenic gene expression and reducing cartilage degradation. To enable targeted delivery, a novel injectable hydr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Hyaluronic AcidMesenchymal Stem CellsHumansOsteoarthritisAnimalsChondrogenesisHydrogelsChondrocytesCell DifferentiationMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research